ReviewBioconjugate chemistry2015
Synthetic Strategies for Engineering Intravenous Hemostats.
Review in Bioconjugate chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Platelet Transfusions: Current Practices and Emerging Alternatives in the United States.Life (Basel, Switzerland) · 2025Review
- Computer-Aided Construction and Evaluation of Poly-L-Lysine/Hyodeoxycholic Acid Nanoparticles for Hemorrhage and Infection Therapy.Pharmaceutics · 2024Article
- Engineering a Two-Component Hemostat for the Treatment of Internal Bleeding through Wound-Targeted Crosslinking.Advanced healthcare materials · 2023Article
- Platelet-Inspired Intravenous Nanomedicine for Injury-Targeted Direct Delivery of Thrombin to Augment Hemostasis in Coagulopathies.ACS nano · 2022Article
- Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.Biophysical reviews · 2022Review
- Article
- Recent advances in biopolymer-based hemostatic materials.Regenerative biomaterials · 2022Review
- Peptide-based topical agents and intravenous hemostat for rapid hemostasis.RSC medicinal chemistry · 2020Review
- Hemostatic agents for prehospital hemorrhage control: a narrative review.Military Medical Research · 2020Review
- Hemoglobin-based Oxygen Carriers: Current State-of-the-art and Novel Molecules.Shock (Augusta, Ga.) · 2019Review
- Biomimetic Strategies To Treat Traumatic Brain Injury by Leveraging Fibrinogen.Bioconjugate chemistry · 2019Review
- Cuboidal tethered cyclodextrin frameworks tailored for hemostasis and injured vessel targeting.Theranostics · 2019Article
- Bio-inspired nanomedicine strategies for artificial blood components.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.Journal of thrombosis and haemostasis : JTH · 2017Article
- Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions.ACS omega · 2016Article
- Platelet-mimetic strategies for modulating the wound environment and inflammatory responses.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Halting hemorrhage with self-propelling particles and local drug delivery.Thrombosis research · 2016Review
- Materials design at the interface of nanoparticles and innate immunity.Journal of materials chemistry. B · 2016Article
- Nanofibrous Snake Venom Hemostat.ACS biomaterials science & engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
While there are currently many well-established topical hemostatic agents for field administration, there are still limited tools to staunch bleeding at less accessible injury sites. Current clinical methods to restore hemostasis after large volume blood loss include platelet and clotting factor transfusion, which have respective drawbacks of short shelf life and risk of viral transmission. Therefore, synthetic hemostatic agents that can be delivered intravenously and encourage stable clot formation after localizing to sites of vascular injury are particularly appealing. In the past three decades, platelet substitutes have been prepared using drug delivery vehicles such as liposomes and PLGA nanoparticles that have been modified to mimic platelet properties. Additionally, structural considerations such as particle size, shape, and flexibility have been addressed in a number of reports. Since platelets are the first responders after vascular injury, platelet substitutes represent an important class of intravenous hemostats under development. More recently, materials affecting fibrin formation have been introduced to induce faster or more stable blood clot formation through fibrin cross-linking. Fibrin represents a major structural component in the final blood clot, and a fibrin-based hemostatic mechanism acting downstream of initial platelet plug formation may be a safer alternative to platelets to avoid undesired thrombotic activity. This Review explores intravenous hemostats under development and strategies to optimize their clotting activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.